Research assay kit Dapreen®

for tumour detectionfor genestissue

With the effective control of acute infectious diseases and the extension of human average lifespan, cancer has become one of the major diseases seriously endangering human health, with aging accelerating the incidence and treatment pressure, especially for tumors, including cancer (similar to malignant tumors). Cancer is one of the top two leading causes of death for residents aged 30-69 in most countries. An important tool throughout the entire cancer management lifecycle is cancer molecular testing. Depending on the type, combination, and purpose of the detected biomarkers, it provides essential information about the occurrence, heterogeneity, progression, and prognosis of the disease, enabling effective intervention and treatment. Tumor driver genes can provide insights into the progression of cancer and can be used to assess prognosis, recurrence, and metastatic risks. Genes related to drug response can help guide medication choices, offering information on drug sensitivity or resistance. Understanding the genetic status of a tumor forms the foundation for developing treatment plans. By selecting the appropriate genes, it's possible to achieve more precise cancer treatment, ensuring the maximum benefit from clinical therapy. DETECTION CONTENT All-in-one test for 175 cancer-related genes Pan Solid Tumor Sequencing Panel(175 genes) is designed to identify all classes of actionable genomic alterations, including SNV，SNP, CNV, InDels, and Fusions, across a total of 175 cancer-related genes.